[Translation] Evaluation of YK-029A tablets compared with platinum doublet chemotherapy in the first-line treatment of patients with locally advanced or advanced EGFR exon 20 insertion mutations
A randomized, open-label, multi-center phase III clinical study of efficacy and safety in patients with metastatic non-small cell lung cancer
评估 YK-029A 片对比含铂双药化疗一线治疗 EGFR ex20ins 突变的局部晚期或转移性NSCLC 患者的有效性;评估 YK-029A 片对比含铂双药化疗一线治疗 EGFR ex20ins 突变的局部晚期或转移性 NSCLC 患者的安全性;评估 YK-029A 片对比含铂双药化疗一线治疗 EGFR ex20ins 突变的局部晚期或转移性 NSCLC 患者的疾病相关症状及健康相关生活质量的影响。
[Translation] To evaluate the effectiveness of YK-029A tablets compared with platinum-containing double-drug chemotherapy in the first-line treatment of locally advanced or metastatic NSCLC patients with EGFR ex20ins mutation; Safety in NSCLC patients; evaluating the effect of YK-029A tablets compared with platinum doublet chemotherapy first-line treatment on disease-related symptoms and health-related quality of life in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.